Recent advances in EGFR-targeted therapies for non-small cell lung cancer
This review discusses recent advances in EGFR-targeted therapies within the molecular landscape of classical and uncommon EGFR mutations, focusing on frontline intensification strategies in metastatic disease—specifically TKI combinations with chemotherapy or bispecific antibodies or bispecific antibodies—and emerging post-progression strategies to overcome acquired resistance mechanisms.